ArticlePediatric research2026
Intraperitoneal rescue stem cell therapy in experimental NEC mitigates intestinal, pulmonary, and neuroinflammatory injury in mice.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Application of Human Umbilical Cord Mesenchymal Stem Cells and Their Derived Exosomes in Gastrointestinal Diseases.International journal of nanomedicine · 2026Review
- Pathogenesis of necrotizing enterocolitis: mechanisms and mediators.World journal of pediatric surgery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNecrotizing enterocolitis (NEC) is a devastating condition associated with long-term complications including NDI (neurodevelopmental impairment), chronic lung disease, and intestinal complications. Umbilical-cord-derived mesenchymal stem cells (USCs) have been shown to improve intestinal outcomes when given prophylactically in preclinical NEC models. We hypothesized that intervention with USCs following onset of experimental NEC would also improve outcomes.
methodsNEC was induced in 5-day-old mouse pups through formula gavage, hypoxia, and hypothermia. Control pups were left with mother (BF ctrl, n = 21). Experimental animals were given an intraperitoneal (IP) injection of either USCs (NEC + USC, n = 16) or sterile PBS (NEC + PBS, n = 18) on PND(postnatal) 7. On PND 9, pups were euthanized, intestinal and lung tissues were H&E stained and homogenized for cytokine assessment, while brain microglia were analyzed via immunohistochemistry.
resultsWhen compared to the NEC + PBS group, the NEC + USC group showed improved clinical scores, intestinal and lung histology, and an improved cytokine profile. Brain microglia were more characteristic of a resting state, with increased branching and complexity that was similar to breast-fed controls.
conclusionsThese findings suggest that intraperitoneal USC administration after NEC onset improves clinical outcomes and reduces intestinal, pulmonary, and neuronal injury-highlighting its potential as a therapy after onset of experimental NEC. IMPACT: Umbilical-cord-derived mesenchymal stem cells (USCs) can improve outcomes in NEC even after its onset. This study is the first murine model to show that USCs serve as an effective rescue therapy-demonstrating significant improvements in clinical scores, intestinal health, lung function, and brain microglia activity. The research suggests that IP USCs may reduce secondary organ damage and enhance long-term outcomes for affected infants, paving the way for future pre-clinical and clinical trials in the neonatal care of this devastating disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.